Payment overview · 2025
General Payments
$415.71
15 reported records · 6 companies
Healthcare provider profile · identity verified
Aaron Daniel Brown, MD
Allopathic & Osteopathic Physicians|Family Medicine · GASTONIA, NC · NPI 1730175456
Verified facts
What the public records show
CMS Open Payments records show Aaron Daniel Brown, MD received $415.71 in general payments during 2025 across 15 reported records.
AstraZeneca Pharmaceuticals LP accounted for 34.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Mounjaro, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 402 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $145.21 | 34.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $103.42 | 24.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $72.18 | 17.4% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.92 | 11.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.62 | 6.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.36 | 4.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $415.71 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $116.34 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $76.81 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $76.81 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.57 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $55.57 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.92 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.87 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 141 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 402 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 69 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
69 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
402 | 55 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
139 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
141 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 839 | 211 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 596 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 485 | 141 |
| Levothyroxine Sodium | Levothyroxine Sodium | 421 | 98 |
| Mounjaro | Tirzepatide | 402 | 55 |
| Losartan Potassium | Losartan Potassium | 398 | 99 |
| Omeprazole | Omeprazole | 390 | 116 |
| Furosemide | Furosemide | 376 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 344 | 82 |
| Pantoprazole Sodium | Pantoprazole Sodium | 330 | 72 |
| Gabapentin | Gabapentin | 306 | 63 |
| Tramadol Hcl | Tramadol Hcl | 267 | 49 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 260 | 37 |
| Alprazolam | Alprazolam | 236 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 58 |
| Clonazepam | Clonazepam | 221 | 46 |
| Lisinopril | Lisinopril | 221 | 65 |
| Montelukast Sodium | Montelukast Sodium | 210 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 201 | 51 |
| Trazodone Hcl | Trazodone Hcl | 193 | 53 |
| Tizanidine Hcl | Tizanidine Hcl | 171 | 47 |
| Spironolactone | Spironolactone | 168 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 165 | 58 |
| Metformin Hcl | Metformin Hcl | 165 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 158 | 38 |
| Metformin Hcl Er | Metformin Hcl | 156 | 40 |
| Prednisone | Prednisone | 153 | 97 |
| Carvedilol | Carvedilol | 152 | 39 |
| Sertraline Hcl | Sertraline Hcl | 148 | 44 |
| Eliquis | Apixaban | 141 | 27 |
| Ozempic | Semaglutide | 139 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 35 |
| Pregabalin | Pregabalin | 136 | 35 |
| Mirtazapine | Mirtazapine | 127 | 33 |
| Lorazepam | Lorazepam | 123 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 121 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 31 |
| Allopurinol | Allopurinol | 111 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 111 | 25 |
| Ezetimibe | Ezetimibe | 108 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 32 |
| Meloxicam | Meloxicam | 106 | 28 |
| Potassium Chloride | Potassium Chloride | 106 | 35 |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 106 | 20 |
| Finasteride | Finasteride | 104 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 94 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 23 |
| Ipratropium Bromide | Ipratropium Bromide | 92 | 27 |
| Telmisartan | Telmisartan | 91 | 24 |
| Cephalexin | Cephalexin | 90 | 73 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 86 | 15 |
| Alendronate Sodium | Alendronate Sodium | 85 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 17 |
| Simvastatin | Simvastatin | 84 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 82 | 18 |
| Buspirone Hcl | Buspirone Hcl | 81 | 21 |
| Synthroid | Levothyroxine Sodium | 80 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 79 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 77 | 26 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 76 | 25 |
| Xarelto | Rivaroxaban | 76 | 11 |
| Celecoxib | Celecoxib | 71 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 69 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 69 | 22 |
| Jardiance | Empagliflozin | 64 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 16 |
| Famotidine | Famotidine | 60 | 20 |
| Dexamethasone | Dexamethasone | 59 | 49 |
| Digoxin | Digoxin | 59 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 59 | 17 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 58 | 14 |
| Azithromycin | Azithromycin | 57 | 53 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 42 |
| Hydrocortisone | Hydrocortisone | 56 | 29 |
| Diazepam | Diazepam | 54 | 11 |
| Bupropion Xl | Bupropion Hcl | 53 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 53 | 14 |
| Azelastine Hcl | Azelastine Hcl | 52 | 21 |
| Cefdinir | Cefdinir | 52 | 44 |
| Promethazine Hcl | Promethazine Hcl | 51 | suppressed |
| Repatha Sureclick | Evolocumab | 50 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 42 |
| Ibuprofen | Ibuprofen | 49 | 15 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | suppressed |
| Chlorthalidone | Chlorthalidone | 46 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 42 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 11 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 39 | suppressed |
| Glipizide Er | Glipizide | 39 | 13 |
| Nystatin | Nystatin | 39 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 36 | suppressed |
| Lactulose | Lactulose | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 33 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Valsartan | Valsartan | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | suppressed |
| Mupirocin | Mupirocin | 31 | 18 |
| Ondansetron Odt | Ondansetron | 31 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 30 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 21 |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 28 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 28 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | 11 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | 15 |
| Nitroglycerin | Nitroglycerin | 22 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Roflumilast | Roflumilast | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Nexium | Esomeprazole Magnesium | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Amoxicillin | Amoxicillin | 17 | 17 |
| Cefuroxime | Cefuroxime Axetil | 17 | 14 |
| Topiramate | Topiramate | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Wegovy | Semaglutide | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Risperidone | Risperidone | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $415.71 · 15 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, ELIQUIS, LINZESS, MOUNJARO, NURTEC ODT, QULIPTA, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error